A federal judge has refused to stay the upcoming trial in a reverse-payment settlement antitrust case while the remaining defendants await the Third Circuit’s review of a class certification ruling.
Trial is scheduled to begin Feb. 2, 2016, in the case King Drug Co. of Florence v. Cephalon, a long-running suit by several different classes of plaintiffs who argued the reverse-payment settlements Cephalon entered with four generic pharmaceutical companies to delay the entry of a generic version of Provigil to market was anti-competitive and caused them to pay more for the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
